CEVA Logistics has launched a new sub-brand, CEVA Forpatients, that offers healthcare and pharmaceutical companies end-to-end logistics solutions.
As part of the suite of solutions, the company is also introducing a new temperature-sensitive logistics product that will begin service in the second quarter of 2021.
The CEVA Forpatients service includes temperature-sensitive solutions, pharma and biopharma, medical devices, consumer health, hospital and home care, as well as diagnostic and laboratory services. The company is also launching an advertising and social media campaign to show how logistics solutions support common medical procedures and healthcare needs.
CEVA’s healthcare solutions are GxP and GDP compliant and meet all national and international regulatory requirements. Specific regulation and compliance information, as well as additional information about CEVA’s healthcare solutions can be found on the dedicated website www.cevalogisticsforpatients.com.
The new CEVA Logistics’ solution requires investment in temperature-controlled facilities around the world. With the support of its parent company, the CMA CGM Group, a world leader in shipping and logistics, CEVA has committed to operating a network of more than 40 such airfreight stations by the end of 2021. Some of the stations will also offer other services, such as contract logistics support.
In all, the stations will allow CEVA to serve major healthcare gateways in regional markets, and supply more than 1,450 healthcare trade lanes globally. Through the global network, CEVA will welcome a broad range of customer shipments in conjunction with its temperature-sensitive packaging solutions, including active and passive packaging, as well as solutions for out-of-gauge goods.
As part of its product offerings, CEVA will provide visibility and monitoring solutions through embedded location and temperature IoT devices. Information will flow into the company’s Matrix supply chain management tool, as well as its global control tower technology for 24/7 shipment monitoring. This multi-layered approach ensures shipments are maintained at required temperatures — a major concern for healthcare customers.
With vaccine and medicine transport growing globally, CEVA will focus its efforts on the 2- to 8-degree Celsius spectrum of products, including certain Covid-19 vaccines, though the company is capable of supporting customers with products, including vaccines, requiring lower temperatures throughout transport.
In addition, CEVA’s approach includes lane risk assessment, performance and capability management as well as a fully integrated cold chain transportation and storage management solution.The company also provides insight on the sustainability and carbon impact of various routing, packaging and mode of transport choices.